- Home
- LQDA vs BXC Comparison
LQDA vs BXC Comparison
Compare LQDA & BXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LQDA
- BXC
- Stock Information
- Founded
- LQDA 2004
- BXC 2004
- Country
- LQDA United States
- BXC United States
- Employees
- LQDA N/A
- BXC N/A
- Industry
- LQDA Biotechnology: Pharmaceutical Preparations
- BXC Wholesale Distributors
- Sector
- LQDA Health Care
- BXC Consumer Discretionary
- Exchange
- LQDA Nasdaq
- BXC Nasdaq
- Market Cap
- LQDA 856.5M
- BXC 1.0B
- IPO Year
- LQDA 2018
- BXC 2004
- Fundamental
- Price
- LQDA $10.65
- BXC $127.54
- Analyst Decision
- LQDA Strong Buy
- BXC Strong Buy
- Analyst Count
- LQDA 8
- BXC 3
- Target Price
- LQDA $27.14
- BXC $135.67
- AVG Volume (30 Days)
- LQDA 773.7K
- BXC 62.5K
- Earning Date
- LQDA 11-13-2024
- BXC 10-29-2024
- Dividend Yield
- LQDA N/A
- BXC N/A
- EPS Growth
- LQDA N/A
- BXC N/A
- EPS
- LQDA N/A
- BXC 3.41
- Revenue
- LQDA $15,610,000.00
- BXC $2,954,424,000.00
- Revenue This Year
- LQDA N/A
- BXC N/A
- Revenue Next Year
- LQDA $227.73
- BXC $4.71
- P/E Ratio
- LQDA N/A
- BXC $37.43
- Revenue Growth
- LQDA N/A
- BXC N/A
- 52 Week Low
- LQDA $6.69
- BXC $85.98
- 52 Week High
- LQDA $16.99
- BXC $132.67
- Technical
- Relative Strength Index (RSI)
- LQDA 52.84
- BXC 67.06
- Support Level
- LQDA $9.93
- BXC $119.03
- Resistance Level
- LQDA $10.95
- BXC $123.54
- Average True Range (ATR)
- LQDA 0.45
- BXC 4.10
- MACD
- LQDA -0.02
- BXC 0.23
- Stochastic Oscillator
- LQDA 67.14
- BXC 100.00
About LQDA Liquidia Corporation
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
About BXC Bluelinx Holdings Inc.
BlueLinx Holdings Inc is engaged in the wholesale distribution of residential and commercial building products. Its business products are split into two categories: Structural products include items such as lumber, plywood, oriented strand board, rebar, and remesh and Specialty products include items such as engineered wood, siding, millwork, outdoor living, specialty lumber and panels, and industrial products. The company's operations are carried out throughout the United States.